Literature DB >> 21958855

Radiotracer properties determined by high performance liquid chromatography: a potential tool for brain radiotracer discovery.

Adriana Alexandre S Tavares1, James Lewsey, Deborah Dewar, Sally L Pimlott.   

Abstract

INTRODUCTION: Previously, development of novel brain radiotracers has largely relied on simple screening tools. Improved selection methods at the early stages of radiotracer discovery and an increased understanding of the relationships between in vitro physicochemical and in vivo radiotracer properties are needed. We investigated if high performance liquid chromatography (HPLC) methodologies could provide criteria for lead candidate selection by comparing HPLC measurements with radiotracer properties in humans.
METHODS: Ten molecules, previously used as radiotracers in humans, were analysed to obtain the following measures: partition coefficient (Log P); permeability (P(m)); percentage of plasma protein binding (%PPB); and membrane partition coefficient (K(m)). Relationships between brain entry measurements (Log P, P(m) and %PPB) and in vivo brain percentage injected dose (%ID); and K(m) and specific binding in vivo (BP(ND)) were investigated. Log P values obtained using in silico packages and flask methods were compared with Log P values obtained using HPLC.
RESULTS: The modelled associations with %ID were stronger for %PPB (r(2)=0.65) and P(m) (r(2)=0.77) than for Log P (r(2)=0.47) while 86% of BP(ND) variance was explained by K(m). Log P values were variable dependant on the methodology used.
CONCLUSIONS: Log P should not be relied upon as a predictor of blood-brain barrier penetration during brain radiotracer discovery. HPLC measurements of permeability, %PPB and membrane interactions may be potentially useful in predicting in vivo performance and hence allow evaluation and ranking of compound libraries for the selection of lead radiotracer candidates at early stages of radiotracer discovery.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958855     DOI: 10.1016/j.nucmedbio.2011.06.011

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  6 in total

1.  Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [(11)C]ME@HAPTHI.

Authors:  Christina Rami-Mark; Neydher Berroterán-Infante; Cecile Philippe; Stefanie Foltin; Chrysoula Vraka; Alexander Hoepping; Rupert Lanzenberger; Marcus Hacker; Markus Mitterhauser; Wolfgang Wadsak
Journal:  EJNMMI Res       Date:  2015-06-10       Impact factor: 3.138

2.  Assessment of [125I]WYE-230949 as a novel histamine H3 receptor radiopharmaceutical.

Authors:  David Y Lewis; Sue Champion; David Wyper; Deborah Dewar; Sally Pimlott
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

3.  A novel 18F-labelled high affinity agent for PET imaging of the translocator protein.

Authors:  Adele Blair; Filip Zmuda; Gaurav Malviya; Adriana A S Tavares; Gilles D Tamagnan; Anthony J Chalmers; Deborah Dewar; Sally L Pimlott; Andrew Sutherland
Journal:  Chem Sci       Date:  2015-05-27       Impact factor: 9.825

4.  PET Imaging of the Adenosine A2A Receptor in the Rotenone-Based Mouse Model of Parkinson's Disease with [18F]FESCH Synthesized by a Simplified Two-Step One-Pot Radiolabeling Strategy.

Authors:  Susann Schröder; Thu Hang Lai; Magali Toussaint; Mathias Kranz; Alexandra Chovsepian; Qi Shang; Sladjana Dukić-Stefanović; Winnie Deuther-Conrad; Rodrigo Teodoro; Barbara Wenzel; Rareş-Petru Moldovan; Francisco Pan-Montojo; Peter Brust
Journal:  Molecules       Date:  2020-04-02       Impact factor: 4.411

5.  Preparation and First Preclinical Evaluation of [(18)F]FE@SNAP: A Potential PET Tracer for the Melanin-Concentrating Hormone Receptor-1 (MCHR1).

Authors:  Cécile Philippe; Lukas Nics; Markus Zeilinger; Eva Schirmer; Helmut Spreitzer; Georgios Karanikas; Rupert Lanzenberger; Helmut Viernstein; Wolfgang Wadsak; Markus Mitterhauser
Journal:  Sci Pharm       Date:  2013-07-01

6.  An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.

Authors:  Filip Zmuda; Adele Blair; Maria Clara Liuzzi; Gaurav Malviya; Anthony J Chalmers; David Lewis; Andrew Sutherland; Sally L Pimlott
Journal:  J Med Chem       Date:  2018-04-19       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.